MBRX Stock Summary and Trading Ideas (Moleculin Biotech | NASDAQ:MBRX)

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Moleculin Biotech trades on the NASDAQ stock market under the symbol MBRX.

As of July 1, 2026, MBRX stock price declined to $2.69 with 547,054 million shares trading.

MBRX has a beta of -1.12, meaning it tends to be less sensitive to market movements. MBRX has a correlation of 0.01 to the broad based SPY ETF.

MBRX has a market cap of $14.35 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, MBRX traded as high as $393.75 and as low as $1.79.

The top ETF exchange traded funds that MBRX belongs to (by Net Assets): VXF.

MBRX has underperformed the market in the last year with a price return of -64.4% while the SPY ETF gained +21.9%. However, in the short term, MBRX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +20.1% vs +18.3% return in SPY. But in the last 2 weeks, MBRX shares have been beat by the market, returning -0.4% compared to an SPY return of -0.4%.

MBRX support price is $2.57 and resistance is $3.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBRX shares will trade within this expected range on the day.